CLINICAL_TRIALS ClinicalTrials.gov record update

Tislelizumab Combined With Liposomal Doxorubicin and Ifosfamide as First-line Treatment for Patients With Specified Subtypes of Unresectable or Metastatic Soft Tissue Sarcoma: a Multi-center, Single-arm, Prospective Phase II Clinical Trial

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06849986
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:40.800343+00:00
Published At: 2026-01-08T00:00:00+00:00
Record Updated At: 2026-01-08
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Soft Tissue Sarcomas", "Angiosarcoma", "Fibrosarcoma", "Leiomyosarcoma", "Pleomorphic Liposarcoma", "Malignant Peripheral Nerve Sheath Tumor (MPNST)", "Desmoplastic Small Round Cell Tumor"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-01-08"
protocolSection.identificationModule.nctId: "NCT06849986"
protocolSection.identificationModule.officialTitle: "Tislelizumab Combined With Liposomal Doxorubicin and Ifosfamide as First-line Treatment for Patients With Specified Subtypes of Unresectable or Metastatic Soft Tissue Sarcoma: a Multi-center, Single-arm, Prospective Phase II Clinical Trial"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.